1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/24174
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMountzios, G.en
dc.contributor.authorDimopoulos, M. A.en
dc.contributor.authorBamias, A.en
dc.contributor.authorPapadopoulos, G.en
dc.contributor.authorKastritis, E.en
dc.contributor.authorSyrigos, K.en
dc.contributor.authorPavlakis, G.en
dc.contributor.authorTerpos, E.en
dc.date.accessioned2015-11-24T19:38:44Z-
dc.date.available2015-11-24T19:38:44Z-
dc.identifier.issn0284-186X-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/24174-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectBone Neoplasms/*diagnosis/metabolism/*secondaryen
dc.subject*Bone Remodelingen
dc.subjectBone and Bones/*pathologyen
dc.subjectBreast Neoplasms/metabolism/pathologyen
dc.subjectDown-Regulationen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectLung Neoplasms/metabolism/pathologyen
dc.subjectMaleen
dc.subjectOsteoblasts/metabolismen
dc.subjectOsteopontin/analysis/metabolismen
dc.subjectOsteoprotegerin/*blood/metabolismen
dc.subjectProstatic Neoplasms/metabolism/pathologyen
dc.subjectRANK Ligand/*blood/metabolismen
dc.subjectSkeletonen
dc.subjectTumor Markers, Biological/*blood/metabolismen
dc.subjectUp-Regulationen
dc.titleAbnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeletonen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1080/02841860600635870-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/17453373-
heal.identifier.secondaryhttp://informahealthcare.com/doi/pdfplus/10.1080/02841860600635870-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2007-
heal.abstractThe role of receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) system, and osteopontin (OPN) was studied in patients with solid tumors metastatic to the bone in relation to the type of malignancy and the neoplastic burden to the skeleton. Levels of soluble RANKL (sRANKL), OPG and OPN were assessed in 61 patients with breast, lung and prostate cancer with newly-diagnosed metastasis to the bone, in parallel with bone resorption [C-telopeptide of type-I collagen (CTX), tartrate-resistant acid phosphatase-5b (TRACP-5b)] and bone formation markers [bone-alkaline phosphatase (bALP), osteocalcin (OC), and C-terminal propeptide of collagen type-I (CICP)]. Patients had elevated serum levels of sRANKL, OPG, OPN, TRACP-5b, and bALP, and reduced OC levels compared to controls. OPG correlated with the extent of metastatic bone burden. Patients with breast and lung cancer shared increased levels of sRANKL, OPG, and OPN whereas prostate cancer patients had elevated values of OPG and bALP only. These results suggest that patients with solid tumors metastatic to the bone have severe disruption of the sRANKL/OPG axis. Breast and lung cancer seem to exert their osteolytic action through upregulation of the sRANKL/OPG system and OPN, whereas prostate cancer seems to provoke profound elevation of OPG levels only, thus leading to increased osteoblastic activity.en
heal.journalNameActa Oncolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
File Description SizeFormat 
Mountzios-2007-Abnormal bone remode.pdf127.02 kBAdobe PDFView/Open    Request a copy
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons